Journey Medical
DERM
36 hedge funds and large institutions have $12.2M invested in Journey Medical in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
3% more funds holding
Funds holding: 35 → 36 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.2% less ownership
Funds ownership: 16.85% → 14.64% (-2.2%)
8% less capital invested
Capital invested by funds: $13.3M → $12.2M (-$1.12M)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$100K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$76.8K |
| 3 |
TAM
Titleist Asset Management
San Antonio,
Texas
|
+$73.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$66.3K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$59.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$837K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$271K |
| 3 |
Walleye Capital
New York
|
-$208K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$113K |
| 5 |
RA
Royce & Associates
New York
|
-$71.4K |
DERM Hedge Fund Activity: Q3 2024 in Review
36 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q3 2024, worth a combined $12.2M — down 8.4% from $13.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DERM positions and 4 closed out — a net gain of 2 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was Cambridge Investment Research Advisors, adding an estimated $100K. The largest seller was Tang Capital Management, exiting entirely with an estimated $837K sold.
- 36 institutional investors held Journey Medical (DERM) as of Q3 2024, up from 35 in Q2 2024.
- Funds reported $12.2M of Journey Medical stock for Q3 2024, down 8.4% quarter-over-quarter.
- 6 funds opened new Journey Medical positions in Q3 2024 and 4 closed out, a net change of +2 holders.
- The largest Journey Medical buyer in Q3 2024 was Cambridge Investment Research Advisors, an estimated $100K added.
- The largest Journey Medical seller in Q3 2024 was Tang Capital Management, an estimated $837K sold.
Based on aggregated 13F filings for Q3 2024.